First patients dosed in groundbreaking trial targeting a common Cancer-Causing gene
NCT ID NCT06364696
Summary
This is the first time a new drug called ASP4396 is being given to people. The study aims to find a safe dose and understand how the body handles it. It is for adults with advanced solid tumors that have spread and carry a specific genetic change called KRAS G12D, who have few other treatment options. The main goal is to check for side effects and see how well people tolerate the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
NEXT Oncology Dallas
Irving, Texas, 75039, United States
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Rochester
Rochester, New York, 14627, United States
Conditions
Explore the condition pages connected to this study.